# OnCo record lutathera (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lutathera/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lutathera" ;
  schema:name "Lutetium-177 dotatate"@en ;
  schema:description "Lutetium-177 dotatate was the first modern radioligand therapy (2018), for neuroendocrine tumours, and is now used in first line."@en ;
  schema:url <https://onco.cc/drugs/lutathera/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lutetium_(177Lu)_oxodotreotide> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27273888> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lutetium-177%20dotatate> ;
  onco:status "approved" ;
  onco:modality "Radioligand therapy (beta)" ;
  schema:alternateName "Lutathera" ;
  onco:approval "US 2018: SSTR+ GEP-NETs", "US 2024: Paediatric ≥12 years; first-line (NETTER-2 label)", "EU 2017: First approval globally (Sep 2017)" ;
  onco:related <https://onco.cc/biomarkers/sstr-pet-expression/> ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/small-intestinal-net/>, <https://onco.cc/cancers/pancreatic-net/>, <https://onco.cc/cancers/grade-3-net/>, <https://onco.cc/cancers/metastatic-ppgl/>, <https://onco.cc/cancers/esthesioneuroblastoma/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/prrt-term/> ;
  onco:trials <https://onco.cc/trials/netter-1/>, <https://onco.cc/trials/nct04711135/>, <https://onco.cc/trials/nct05142696/>, <https://onco.cc/trials/nct03972488/> .